Caribou Biosciences, Inc. (CRBU) Stock Profile — Insider Trades & Financials

Revenue$3.9M

Net Income-$26.5M

EPS$-1.59

Market Cap$188.4M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Rachel Haurwitz

CEO & Executive Director

Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Founded: 2011
Employees: 97
Headquarters

⚡

Core Efficiency

ROE?

-21.68%

ROA?

-15.10%

D/E Ratio?

0.44

Op. Margin?

-721.97%

📊

Profitability Ratios

Net Margin?

-672.11%

Loading company sections...

Caribou Biosciences, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness